Without blood clots and bleeding
The results of the clinical study demonstrated the ability of the experimental antiplatelet compound ACT017 to inhibit the formation of blood clots without provoking bleeding, which is a common and potentially life-threatening side effect of modern methods of anticoagulation therapy.
According to the head of the study, Dr. Martin Jandrot-Perrus from the French National Institute of Health and Medical Research, today there is an obvious need for a new antiplatelet agent that stops the process of platelet aggregation and the formation of blood clots without the risk of bleeding. Such therapy would significantly improve and expand our therapeutic arsenal in the treatment of acute strokes.
The experimental drug is a compound whose active component is an antibody that inhibits platelet aggregation by targeting the protein glycoprotein VI contained in platelets. This protein is necessary for the formation of blood clots, but it is not involved in the regulation of bleeding in any way. This makes glycoprotein VI an ideal target for a drug that inhibits the process of thrombosis without increasing the risk of bleeding.
The study conducted by the authors involved 36 healthy volunteers (23 women and 13 men) aged 22 to 65 years. They were divided into 6 groups who received intravenous injections of various doses of the drug for 6 months (ranging from 62.5 mg to 2,000 mg).
All doses of the drug were well tolerated by the participants and did not cause serious side effects. Especially important is the fact that the drug did not cause a significant indicator of an increased risk of a life-threatening increase in bleeding time. In addition, the results of the study showed that the strength and duration of the therapeutic drug depended on its dose, and the maximum effectiveness and duration fell on a dose of 2000 mg. The most common side effects were mild to moderate headaches and unpleasant sensations in the head, which disappeared during the study.
According to the authors, the results obtained are very encouraging, as they indicate that the drug is well tolerated and does not cause bleeding even at dosages twice the estimated therapeutic doses. Another important point is that the effect of the drug on platelets is rapid, specific and almost completely reversible within 24 hours.
Article by Christine Voors-Pette et al. Safety and Tolerance, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab published in the journal Arteriosclerosis, Thrombosis and Vascular Biology.
Evgenia Ryabtseva, portal "Eternal Youth" http://vechnayamolodost.ru based on the materials of the American Heart Association: Experimental antiplatelet compound for acute stroke shows promise.